Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

AI-powered therapeutic aptamer drug discovery: Targeting the CT-domain of CTGF for duchenne muscular dystrophy.

Acta pharmaceutica Sinica. B·2026

Same author

Dynamic distribution of label-free polysaccharides after intestinal lymphatic absorption.

International journal of biological macromolecules·2026

Same author

From Five-Number Summary to Absolute Heterogeneity: Recent Methodological Advances in Meta-Analysis With Continuous Outcomes.

Journal of evidence-based medicine·2026

Same author

Extracellular vesicles in the tumor microenvironment: Diverse origins, multifaceted functions, and emerging therapeutic opportunities.

Translational research : the journal of laboratory and clinical medicine·2026

Same author

Blocking interaction of sclerostin loop3 with osteoblastic LRP4 counteracts bone loss without increasing arterial stiffness during mechanical unloading.

Journal of orthopaedic translation·2026

Same author

The aberration of key amino acids participated one-carbon metabolism may jeopardize genetic stability in cancer development.

Cell communication and signaling : CCS·2026

Search research articles

相关实验视频

Updated: Jul 8, 2025

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

一个双分子修改策略,用于开发长期持久的骨类合成药性胺体.

Huarui Zhang¹, Sifan Yu^1,2,3, Shuaijian Ni²

¹School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

Molecular therapy. Nucleic acids

|December 11, 2023

概括

核酸亚体的半衰期很短,这限制了它们的使用. 新的合剂 (HC和DA) 与骨类合成胺体 (Apc001) 结合,协同结合人血清白蛋白 (HSA),延长半衰期并增强骨生长.

关键词:

MT:寡核酸:治疗方法和应用.它们是Aptamers.长期持续的修改改变低分子量合剂是一种低分子量合剂.骨质发生不完美 (osteogenesis imperfecta) 是一个不完美的疾病.硬化成硬化在其中.

更多相关视频

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach

Published on: August 26, 2013

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

相关实验视频

Last Updated: Jul 8, 2025

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach

Published on: August 26, 2013

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

科学领域:

生物技术是生物技术.
药物开发药物开发
生物化学生物化学

背景情况:

由于脏过,核酸胺体的半衰期很短,阻碍了它们的治疗应用.
低分子量 (20 kDa) 的阿普坦体低于脏过切线 (30-50 kDa),导致快速清除.
亚胺的有限可药性需要战略来克服药理动力学挑战.

研究的目的:

开发一种新的双分子修饰策略,以增强阿普坦体的药物可用性.
为了延长半衰期,并提高一个向硬质素的阿巴胺 (Apc001) 的骨类合成潜力.
为了研究新型合剂与人血清白蛋白 (HSA) 的协同结合,以稳定阿普坦.

主要方法:

新型合剂的结合,3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) -N-(4-hydroxy-2-oxo-2H-chromen-6-yl) propenamide (HC) 和12-((2,5-dioxopyrrolidin-1-yl) oxy) -12-oxododecanoic 酸 (DA) 的结合,成为一个骨类合成剂的阿巴特马 (Apc001).
形成一个具有与人血清白蛋白 (HSA) 高结合 afinity 的 Apc001OC 结合体.
使用阻断的药理动力学和骨类合成潜力的研究,以阐明HC-DA与HSA结合的协同机制.

主要成果:

Apc001OC结合物证明了与HSA的协同结合,显著延长了aptamer的半衰期.
两周一次服用Apc001OC (50 mg/kg) 的骨类合成药效应与每周一次服用市面上销售的斯克莱洛斯抗体 (25 mg/kg) 的剂量相当.
机制研究证实,HC和DA与HSA的协同结合对增强的药理动力学和骨类合成活性负责.

结论:

使用对HSA的协同结合剂 (HC-DA) 的双分子修饰策略有效地解决了阿胺的短半衰期和可药性限制.
这种方法提供了一种有前途的治疗途径,可以增强骨的合成能力,治疗与骨相关的疾病.
Apc001OC结合物代表了针对硬质素的抗体疗法的一种潜在替代方案.